PVT401, a peptide-MHC nanomedicine, is the second Parvus drug candidate to enter clinical trials. Full Release

PVT201 demonstrated favorable safety, predictable pharmacokinetics, and on-target pharmacodynamic activity in first-in-human study. Full Release

Parvus Therapeutics, a clinical-stage company, announced today that development of PVT401, a novel pMHC nanomedicine (Navacim™) drug candidate, met rigorous prospective nonclinical pharmacology and manufacturing criteria. PVT401 is being developed in collaboration with AbbVie (NYSE: ABBV) as a treatment for inflammatory bowel disease (IBD). Based on this achievement, AbbVie has endorsed the commencement of the next set of IND enabling activities and issued a milestone payment to Parvus. Full Release

Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PVT201 single ascending doses in healthy subjects and primary biliary cholangitis patients. Full Release

Parvus Therapeutics, a private preclinical company developing a pipeline of novel Navacim™ autoimmune disease drug candidates which trigger endogenous generation of regulatory T cells (Tregs) to provide organ specific immunoregulation, is pleased to announce the appointments of Joanne B.L. Tan, PhD as the Senior Vice President of Research and Development and Sarah Grimberg as the Senior Director of Clinical Operations. Full Release

Parvus Therapeutics announces that PVT201 has received Orphan Drug Designation for Primary Biliary Cholangitis and Australian Human Research Ethics Committee approval to begin clinical testing. Full Release

Parvus Therapeutics announced today that it has entered into an exclusive worldwide license collaboration and option agreement with AbbVie Inc. (NYSE: ABBV) for the development and commercialization of novel treatments for Inflammatory Bowel Disease (IBD), utilizing Parvus’ Navacim™ Treg immune tolerization platform technology. Full Release

Parvus Therapeutics announced today the publication of data showing that peptide-MHC class II-coated nanoparticles (Navacims) operate by triggering the expansion of cognate T follicular helper (TFH) cells. Full Release

Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function, today announced an agreement with National Resilience, Inc. (Resilience), for the tech transfer, scale-up and GMP manufacturing of PVT201, Parvus’ lead Navacim™ drug candidate being developed to treat Primary Biliary Cholangitis. Full Release

Parvus Therapeutics is a biopharmaceutical company developing Navacim™ platform based disease-specific immunoregulating therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function. Full Release

Parvus Therapeutics, a biopharmaceutical company focused on the development of medicines using the proprietary platform-based, disease-specific immunoregulator, Navacims™, to treat autoimmune diseases without impairing normal immunity, today announced the appointment of Peter Strumph as Chief Executive Officer and a member of the Board of Directors, Matthew J. Hogan as a member of the Board of Directors, Brendan Classon as Executive Vice President, Research and Development, and Louis Demers as Vice President of Technical Operations. Full Release

Parvus Therapeutics , a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, today announced the appointment of Hugh Young Rienhoff, Jr., M.D., as Chairman of the Board, Charles A. Johnson, M.D., to the Board of Directors, and Alain Delcayre, Ph.D., as Senior Vice President of Research. Full Release

Research underpins part of the recently executed license and collaboration agreement to develop, manufacture and commercialize Navacim™therapeutics for treatment of gastrointestinal inflammatory diseases, including autoimmune liver disease Full Release

Parvus Eligible to Receive Upfront and Milestone Payments Exceeding $800 Million Plus Royalties on Net Sales Full Release

Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Full Release

Parvus Therapeutics today announced the publication in Nature of a seminal paper describing the discovery and applications of a novel therapeutic approach employing nanomedicines, referred to as "Navacims"™, to reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses and restoring the equilibrium of the immune system. Full Release